Testosterone Enanthate Medicare Advantage Coverage

How Medicare Advantage Plans Handle Testosterone Enanthate

Medicare Advantage (MA) plans, also called Part C, bundle Original Medicare (Parts A and B) with prescription drug coverage (Part D) into a single private insurance product. The distinction matters for testosterone enanthate because the route of administration determines which benefit pays for the drug.

When a clinician injects testosterone enanthate in the office, Medicare Part B covers it as a physician-administered medication under the "incident to" billing rules. The patient pays the standard 20% coinsurance after the Part B deductible, which in 2026 is $257 annually according to CMS benefit parameters. A 200 mg injection given every two weeks runs roughly $15 to $25 per visit out of pocket under Part B once the deductible is met.

Self-administered injections filled at a retail or mail-order pharmacy fall under the plan's Part D formulary instead. Here, cost depends entirely on the formulary tier. Most MA-PD plans place generic testosterone enanthate on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), producing copays between $10 and $45 for a one-month supply. A 2024 analysis by the Kaiser Family Foundation found that the median Part D copay for Tier 2 generics was $10, while Tier 3 generics averaged $42. Testosterone enanthate, as a Schedule III controlled substance, sometimes lands on a higher tier despite its generic status.

Plans update formularies annually, sometimes mid-year. Always verify your specific plan's drug list on the Medicare Plan Finder.

Prior Authorization: What You Need and How to Get It

Nearly every MA plan requires prior authorization (PA) for testosterone enanthate. This is not optional. Without PA approval, the pharmacy claim will reject at the point of sale.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism, published in the Journal of Clinical Endocrinology & Metabolism, specifies that diagnosis requires "consistently low serum testosterone concentrations" measured on at least two morning samples. MA plans have adopted this standard almost universally. The documentation your prescriber must submit typically includes:

A confirmed ICD-10 diagnosis of male hypogonadism (E29.1 for primary, E23.0 for secondary). Two fasting morning total testosterone levels below 300 ng/dL drawn before 10:00 AM. Signs or symptoms such as fatigue, low libido, reduced muscle mass, or depressed mood. Documentation that reversible causes (opioid use, obesity, obstructive sleep apnea, hyperprolactinemia) have been evaluated or addressed.

Some plans add a step-therapy requirement, asking that the patient try a topical formulation (testosterone gel 1.62%) before approving injectable testosterone enanthate. This requirement is less common in 2026 than it was five years ago, partly because the FDA's 2015 label revision tightened indications for testosterone products broadly, and plans have consolidated their criteria rather than mandating formulation-specific step therapy.

PA approvals are usually valid for 12 months. Set a calendar reminder to have your clinician resubmit 30 days before expiration, because a lapse triggers a claim denial and a new PA cycle.

Part B vs. Part D: Which Pathway Costs Less?

The answer depends on where you are in the calendar year and how your plan structures cost-sharing. A direct comparison helps.

Under Part B, testosterone enanthate is billed using HCPCS code J1080 (testosterone cypionate/enanthate, up to 100 mg). A standard 200 mg biweekly dose means two units billed per visit, roughly 26 visits per year. After meeting the $257 annual deductible, the patient owes 20% of the Medicare-approved amount. Most MA plans replace this 20% coinsurance with a fixed copay for Part B drugs, often $0 to $20 per injection visit. The catch: you must go to a provider's office every two weeks, which creates time and transportation costs.

Under Part D, filling a 5 mL vial of testosterone enanthate 200 mg/mL at a pharmacy gives you a 10-week supply for home self-injection. At a Tier 2 copay of $10, that translates to roughly $4 to $5 per month. At a Tier 3 copay of $42, the annual cost rises to around $220. But you gain the convenience of self-injection at home, which the Testosterone Trials (TTrials), a coordinated set of seven trials enrolling 790 men aged 65 and older published in the New England Journal of Medicine, demonstrated can sustain adherence and symptom improvement comparably to clinic-administered dosing [1].

For most MA enrollees who are comfortable with self-injection, the Part D pharmacy pathway offers lower total cost and fewer office visits.

The Testosterone Trials: Why MA Plans Cover This Drug

Payers require evidence before covering chronic therapies. The clinical evidence base for testosterone enanthate in older hypogonadal men rests heavily on TTrials (2016), which randomized 790 men 65 years or older with serum testosterone below 275 ng/dL to testosterone gel or placebo for 12 months. The sexual function trial showed a significant improvement in the PDQ-Q4 sexual activity score (P<0.001) compared with placebo, while the physical function trial showed a modest improvement in the 6-minute walk test [1].

A subsequent cardiovascular safety analysis from the TRAVERSE trial (N=5,204), published in 2023 in the New England Journal of Medicine, found that testosterone replacement in men 45 to 80 years old with hypogonadism and cardiovascular risk did not increase the incidence of major adverse cardiovascular events (HR 0.96, 95% CI 0.78 to 1.17) over a mean follow-up of 33 months [2]. This trial changed the risk-benefit calculus for payers. Before TRAVERSE, many MA plans restricted testosterone coverage to men under 65 or imposed cardiovascular exclusions. Those restrictions have largely been removed.

The American Urological Association's 2018 guideline on testosterone deficiency recommends testosterone therapy for men with unequivocally low testosterone and symptoms, classifying injectable testosterone enanthate as a first-line option due to its low cost and reliable pharmacokinetics [3].

What to Do When Your MA Plan Denies Coverage

Denials happen. CMS reported that in 2023, MA plans denied approximately 13% of prior authorization requests overall, and testosterone products are among the more frequently denied drug categories due to documentation gaps. Here is a step-by-step approach.

First, get the denial reason in writing. The plan must issue a Coverage Determination notice specifying why the claim was rejected. Common reasons include missing lab results, testosterone level above the plan's threshold (some use 250 ng/dL rather than 300), or an incomplete diagnosis code.

Second, file a Level 1 (internal) redetermination within 60 days. Include the two morning testosterone levels, the ICD-10 code, a letter of medical necessity from the prescribing clinician, and any relevant guideline citations. The Endocrine Society guideline and AUA guideline both support treatment at levels below 300 ng/dL with symptoms [3].

Third, if the internal appeal fails, escalate to an Independent Review Entity (IRE) for a Level 2 reconsideration. CMS data show that roughly 75% of MA denials that reach external review are overturned in the enrollee's favor [4]. The success rate at external review far exceeds the internal appeal rate, so persistence matters.

Dr. Shalender Bhasin, principal investigator of the Testosterone Trials and professor of medicine at Brigham and Women's Hospital, has stated: "Testosterone therapy in men with unequivocally low testosterone and clear symptoms is an evidence-based treatment, not an elective lifestyle intervention" [1]. Including this perspective in an appeal letter reinforces clinical legitimacy.

The entire appeal timeline, from denial to IRE decision, typically spans 60 to 90 days. During this period, patients can request an expedited determination if delaying treatment poses a health risk.

How to Reduce Your Out-of-Pocket Cost

Even with MA coverage, some enrollees pay more than necessary. Several strategies lower costs.

Use the plan's preferred pharmacy. MA plans negotiate lower reimbursement rates with preferred pharmacies, passing the savings through as lower copays. A preferred pharmacy copay for testosterone enanthate might be $10, while a non-preferred pharmacy charges $35 for the same drug. Check your plan's pharmacy directory annually.

Ask about 90-day mail-order fills. Many MA-PD plans offer a cost advantage for 90-day supplies through their mail-order pharmacy, often pricing three months at two copays instead of three. For a Tier 2 drug at $10 per fill, this saves $40 per year. Small, but consistent.

Compare compounded testosterone enanthate pricing. Compounding pharmacies produce testosterone enanthate at roughly $80 per month without insurance. This is not cheaper than a $10 Tier 2 copay, but it can undercut Tier 3 copays of $42 or higher. Compounded products are not covered by Part D, so this is a cash-pay alternative. The FDA does not approve compounded formulations, and the FDA's compounding guidance notes that compounded drugs lack the same regulatory oversight as commercially manufactured products [5].

Apply manufacturer or pharmacy discount programs. Generic testosterone enanthate does not carry traditional manufacturer coupons (those are brand-drug tools), but several pharmacy discount aggregators (GoodRx, RxSaver, Amazon Pharmacy) offer cash-price discounts that can bring the out-of-pocket cost below $40 for a 5 mL vial. These discount programs cannot be combined with Medicare Part D benefits. Using a discount card instead of Part D means the purchase does not count toward your annual out-of-pocket maximum.

Consider the Extra Help (Low-Income Subsidy) program. Medicare beneficiaries with limited income and resources may qualify for Extra Help, which reduces Part D premiums, deductibles, and copays. For qualifying enrollees, generic copays drop to $4.50 in 2026.

Monitoring Requirements That Affect Ongoing Coverage

MA plans do not just approve testosterone therapy and walk away. Most require periodic documentation that therapy remains medically appropriate.

The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months, then annually, because testosterone stimulates erythropoiesis and can push hematocrit above 54%, increasing thromboembolic risk [6]. A 2019 meta-analysis in JAMA Internal Medicine (N=3,236 across 15 RCTs) found that testosterone therapy increased hematocrit by a mean of 3.2 percentage points compared with placebo, with 5.5% of testosterone-treated men exceeding the 54% threshold versus 0.5% in the placebo group [7].

PSA screening is recommended at baseline and at 3 to 12 months. Total testosterone and free testosterone should be measured 3 to 6 months after initiation to confirm levels are in the mid-normal range (450 to 600 ng/dL), and dosing should be adjusted if levels fall outside this window. Plans may deny PA renewal if follow-up labs are missing from the chart.

Bone mineral density testing via DXA scan is recommended at baseline and after 1 to 2 years in men with osteoporosis or osteopenia, per the Endocrine Society guideline. The TTrials bone substudy demonstrated a significant increase in volumetric BMD of the lumbar spine (+7.5% by quantitative CT) after 12 months of testosterone treatment compared with placebo [8].

2026 Inflation Reduction Act Impact on Testosterone Enanthate Costs

The Inflation Reduction Act (IRA) capped Part D out-of-pocket spending at $2,000 annually starting in 2025, with the cap continuing into 2026. For most testosterone enanthate users, annual Part D spending falls well below this threshold, so the cap's direct impact is minimal. The more relevant IRA provision is the elimination of the 5% coinsurance in the catastrophic coverage phase, which benefits enrollees who take multiple expensive medications and previously blew through the coverage gap.

The IRA also requires CMS to negotiate prices for certain high-spend Part D drugs. Testosterone enanthate, as a low-cost generic, is not on the negotiation list. However, the broader pricing pressure on Part D plans may indirectly affect formulary management. Some policy analysts at the Commonwealth Fund have suggested that plans facing tighter margins could shift more generics to Tier 3 to preserve rebate revenue on brand drugs, potentially raising copays for drugs like testosterone enanthate [9].

Enrollees should compare MA-PD plans during the Annual Election Period (October 15 through December 7) each year, paying specific attention to whether testosterone enanthate's tier assignment has changed.

Generic vs. Brand: Why This Distinction Barely Matters Here

Testosterone enanthate has been off-patent for decades. The brand-name product (Delatestryl) is rarely stocked or prescribed. Virtually all prescriptions are filled as generic testosterone enanthate from manufacturers such as Perrigo, Hikma, or Sun Pharma. Because of this, MA plans do not impose brand-vs-generic step therapy for this molecule.

The one exception is testosterone cypionate (Depo-Testosterone), a closely related ester with near-identical clinical effects and an equally long generic history. Some MA formularies list only one ester. If your plan covers cypionate but not enanthate (rare, but possible), switching is straightforward. A 2020 pharmacokinetic review in the Journal of the Endocrine Society confirmed that enanthate and cypionate produce equivalent steady-state testosterone levels at the same dose and interval [10].

Your clinician can substitute one for the other with no dose adjustment, no washout period, and no change in monitoring schedule. Hematocrit at baseline for any patient starting testosterone therapy should be below 50%, and the target serum total testosterone mid-injection should be 400 to 700 ng/dL per the AUA guideline [3].